Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Bloomfield
C D
CD
The Ohio State University, Columbus, OH, USA.
Ruppert
A S
AS
Mrózek
K
K
Kolitz
J E
JE
Moore
J O
JO
Mayer
R J
RJ
Edwards
C G
CG
Sterling
L J
LJ
Vardiman
J W
JW
Carroll
A J
AJ
Pettenati
M J
MJ
Stamberg
J
J
Byrd
J C
JC
Marcucci
G
G
Larson
R A
RA
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D050676:Core Binding Factor Alpha 2 Subunit; D003561:Cytarabine / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic
D000964:Antimetabolites, Antineoplastic; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D014157:Transcription Factors; D003561:Cytarabine